Duplex Therapeutics

Duplex Therapeutics has developed a therapeutic platform technology that is based on a newly identified and druggable biological target that has shown to play a key role in specific inflammatory diseases, namely inflammatory bowel disease (IBD) and in two obesity-related liver diseases: non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).